黑料网

Neonatal Screening; MS; NGS

Introduction

Neonatal screening, also known as newborn screening, is a vital public health program that aims to identify congenital and metabolic disorders in newborns shortly after birth. This early detection and intervention can prevent severe health complications and improve the quality of life for affected infants. In recent years, neonatal screening has witnessed significant advancements, revolutionizing the way healthcare professionals approach early diagnosis and treatment [1]. This review article explores the latest developments in neonatal screening techniques, their impact on healthcare, and future prospects for this critical aspect of infant healthcare [2].

Technological advances

Traditionally, neonatal screening relied on dried blood spot testing for a limited set of disorders. However, technological innovations have expanded the scope and accuracy of screening. Liquid chromatographytandem mass spectrometry (LC-MS/MS) has gained popularity for its ability to simultaneously detect multiple metabolic disorders from a single blood sample [3]. Next-generation sequencing (NGS) has revolutionized genetic screening, enabling the identification of a wide range of inherited conditions, including rare diseases with complex genetic origins. These technologies have drastically improved the sensitivity and specificity of neonatal screening, reducing false positives and ensuring timely intervention [4].

Expanded disease panel

One of the most notable advancements in neonatal screening is the expansion of the disease panel. Initially focused on a handful of disorders, modern screening panels now include a more comprehensive list of conditions [5]. This expansion allows for the detection of rare but treatable disorders, such as spinal muscular atrophy and severe combined immunodeficiency. The inclusion of these conditions has significantly improved the overall effectiveness of neonatal screening programs, saving lives and reducing the burden of lifelong healthcare costs [6].

Data integration and informatics

The integration of data and informatics has streamlined neonatal screening processes. Electronic health records (EHRs) now facilitate seamless data exchange between screening laboratories and healthcare providers, ensuring that results are readily available for clinical decision-making [7]. Moreover, artificial intelligence and machine learning algorithms help interpret complex screening data, aiding in the identification of subtle patterns that might indicate the presence of a disorder. These technological advancements have led to more efficient and accurate neonatal screening programs [8 -10].

Challenges and future directions

Despite these remarkable advancements, challenges remain. Ensuring equitable access to neonatal screening, addressing ethical concerns related to genetic information, and maintaining the privacy and security of patient data are ongoing issues. In the future, continued research will likely lead to even more sophisticated screening techniques and a deeper understanding of genetic and metabolic disorders in neonates.

Conclusion

Neonatal screening has come a long way, evolving from a limited screening program to a comprehensive, high-tech approach that can identify a broader range of congenital and metabolic disorders. These advancements have transformed neonatal healthcare, enabling early intervention and improving the lives of countless newborns. With ongoing research and the integration of cutting-edge technologies, neonatal screening is poised to continue saving lives and reducing the burden of disease in the most vulnerable members of our population. As technology and medical knowledge progress, the future of neonatal screening looks promising, offering hope for healthier starts in life for all infants.

1. Jing L, Y Na, L Ying (2014) Balkan Med J 5(1): 64-68.

, ,

2. Al Riyami N (2020) Oman Med J 17(35):133.

, ,

3. Tochie JN (2020)

, ,

4. Raha BK, MJ Alam, MAQ Bhuiyan (2019) Bangladesh Med J 48(3): 21-27.

, ,

5. Raha BK, MJ Alam, MAQ Bhuiyan (2021) Bangladesh Coll Phys Surg 39(1): 4-8.

,

6. Niesłuchowska-Hoxha A (2018) Biomed Res Int 15: 67-71.

, ,

7. Hermansen CL, KN Lorah (2007) Ame fam phy 76(7): 987-994.
8. Alfarwati TW (2019) Medical Archives, 73(3): 183.

, ,

9. Sivanandan S, R Agarwal, A Sethi (2017) Semin Fetal Neonatal Med 22(4): 260-266.

, ,

10. Hubertus J, Plieninger S, Martinovic V, Heinrich M, Schuster T, et al. (2013) Wor J Urol 31: 683-687.

, ,